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Abstract 
Human papillomavirus (HPV) is considered as one of the most common sexually 
transmitted diseases (STD) in the United States. HPV affects boys and girls causing several 
types of cancer and sexually transmitted infections (STI). Only the symptoms associated with 
HPV are treatable. The HPV vaccine has been available for several years for prevention of 
human papillomavirus. The Centers for Disease Control and Prevention (CDC) recommends for 
girls and boys, age 9 and older, to receive the series of three HPV vaccines. Human 
papillomavirus quadrivalent is recommended as the HPV vaccine to give boys. Vaccination for 
boys is recommended as early as 9 years old to the age of 21. Administering the HPV vaccine 
would help lower the rates of HPV, cervical cancer and genital warts. The purpose of this study 
was to determine the number (percentage) of boys, ages 9-21, who were educated on or who 
received the HPV vaccine at their local community clinic. Nola Pender's health promotion 
model (HPM) was used as the framework for this study. Retrospective chart reviews were 
performed on 300 boys, ages 9-21, from three clinics in southeastern United States. Records 
were evaluated to determine if boys received the HPV vaccine or received education on the HPV 
vaccine. Researchers also determined which type of education was given to the patient. 
Conclusion of findings showed the HPV vaccine was given to 25% of males in the age range of 
9-21. Results showed that 40% of the patients received education from the provider about the 
importance and recommendation for the HPV vaccine. The majority of the education given to the 
patients was verbal information on the importance of HPV vaccination. 
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Chapter I 
Dimensions of the Problem 
Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
(STI) in the United States (Centers for Disease Control and Prevention (CDC), 2012). An 
estimated 20 million Americans are infected with HPV and over 6 million people are infected 
each year. There are over 40 different types of HPV which affect the genitals, mouth and throat 
of boys and girls. Cancer of the cervix, vagina, vulva, penis, anus and oropharyngeal area are 
caused by HPV. Most people are not aware of being infected with HPV. HPV is spread through 
vaginal sex, anal sex, oral sex and genital to genital contact with an infected person. Men who 
develop HPV rarely have any symptoms or health problems. Each year in the United States, 400 
men are diagnosed with HPV-related cancer of the penis and 1500 men are diagnosed with HPV-
related cancer of the anus (CDC, 2012). Gay men, bisexual men and men with weakened 
immune systems are more likely to develop HPV-related diseases than healthy men who only 
have sex with women. There are currently no tests available to screen boys. There are only tests 
available to screen women. There are no cures or treatments for the actual human 
papillomavirus. Only the symptoms from the virus can be treated (Cates et al., 2012). 
The CDC (2012) recommends Gardasil® (human papillomavirus quadrivalent), a vaccine 
made by Merck Pharmaceuticals and approved by the FDA, be administered to boys for the 
prevention of HPV. Human papillomavirus quadrivalent is the only vaccine approved to protect 
against HPV types 6, 11, 16 and 18 in boys. By vaccinating boys, ages 9-21, the HPV rates will 
more than likely decrease in the United States. 
Problem Statement 
Human papillomavirus (HPV) is described as the most common sexually transmitted 
infections (STI) in the United States and infects approximately 50% of sexually active men and 
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women (CDC, 2012). In 2006, the HPV vaccine was approved for girls, ages 9-26. The HPV 
vaccine was approved for boys in 2011. In 2011, the CDC recommended that boys as young as 9 
years old to 21 years old be given the HPV vaccine routinely (Rollins, 2011). 
Although the HPV vaccine is available to boys and girls, clinics do not always offer the 
vaccine. Providers also have not educated parents or patients on the importance of the vaccine in 
preventing cancer and sexually transmitted diseases. Therefore, not all boys, ages 9-21, received 
the HPV vaccine or were educated on the HPV vaccine. 
The CDC (2012) recommends that Gardasil® (Human Papillomavirus Quadrivalent), a 
vaccine made by Merck Pharmaceuticals and approved by the FDA, be given to boys for the 
prevention of HPV. Human papillomavirus quadrivalent protects against HPV types 6, 11, 16 
and 18 in girls and boys. Types 6 and 11 cause genital warts in boys and girls. Types 16 and 18 
cause cervical cancer in girls. Human papillomavirus quadrivalent is recommended to be given 
in 3 doses over 6 months. The second dose is to be received 1-2 months after the first dose. The 
third dose is to be given 6 months after the first dose. Results of testing by the FDA showed no 
serious side effects from the injection. Mild side effects include pain at injection site, fever, 
nausea and headache (CDC, 2012). 
Statement of Purpose 
The purpose of this study was to determine if boys, ages 9-21, were educated about the 
HPV vaccine at their local community clinic and if the vaccine was administered. The 
information for this study came from 300 chart reviews performed at three rural clinics in the 
southeastern United States. Physicians and nurse practitioners were the primary health care 
providers at these clinics. The information collected and reviewed for this study was shared with 
the providers to help benefit their practice. The study helped to recognize areas for improvement 
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in regard to providing patients necessary information on receiving the HPV vaccine based on the 
CDC's recommendations. 
Significance of Study 
The significance of vaccinating boys with the HPV vaccine would decrease the spread of 
STI's and lower the rate of cervical cancer in women by preventing the spread of the virus. 
Researching if clinics vaccinated boys, ages 9-21, showed providers the low percentage of 
patients vaccinated. Research also showed providers that little education was provided to the 
patient or parent. Research showed that the education provided to the patient was mainly verbal. 
Based on findings from the research, providers were able to see the need for HPV vaccination 
promotion in their clinic. Researchers shared the results to teach providers that health promotion 
and prevention are needed to lower the spread of the human papillomavirus. After the results 
from our research findings, NP's were able to use the knowledge to better educate and vaccinate 
their patient. By providing more education to parents, they would better understand that their 
sons may play a role in preventing the spread of genital warts. 
Theoretical Framework 
Health promotion is defined as a behavior which arises from one's desire to increase 
well-being and to achieve one's health potential (Phillips et al., 2000). Nola Pender's health 
promotion model (HPM) is a framework for determining factors which influence health 
behaviors. Pender's HPM demonstrates the importance of the client's role in making lifestyle 
changes to promote health. The HPM may be used for any situation in which clients seek 
changing their behavior and environment in order to support healthy behaviors. The HPM is also 
beneficial to professionals interested in promoting health such as our research on HPV 
vaccination. The HPM enables researchers and health professionals to determine ways which 
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influence clients to participate in healthy behaviors. Pender's focus is to keep people healthy and 
to continue to find ways to promote health (Pender & Pender, 1980). 
Health-promoting behavior was not practiced by everyone and this information is 
revealed by our research. Researched showed that only 25% of males received the HPV 
vaccination. Researchers shared the results with providers from the three clinics. Health care 
providers were encouraged by researchers to use the results to better educate the patient and 
parent on the CDC's recommendations for the HPV vaccine. Pender's HPM model was used by 
the researchers when they shared results with health care providers. Sharing the information 
encouraged health care providers to promote healthy behaviors in their patient. 
Questions 
1. Did the Health Care Provider educate the male patient or the parent on the Centers for 
Disease Control and Prevention's recommendations for the Human Papillomavirus 
vaccine? 
2. Was the Human Papillomavirus vaccine administered or prescribed to the patient? 
Definitions 
Health care provider 
Theoretical: An individual who provided preventive, curative or promotional health care 
services in a systematic way to individuals, families or communities. (Taber's Cyclopedic 
Medical Dictionary, 2005). 




Theoretical: Obtaining knowledge regarding a subject through a learning experience 
(Taber's Cyclopedic Medical Dictionary, 2005). 
Operational: Information was provided to males (age 9-21) or to the parent through 
pamphlets, printouts or verbal information about the CDC's recommendations for human 
papillomavirus quadrivalent vaccination. 
Patient 
Theoretical: One who is sick with or being treated for an illness or injury (Taber's 
Cyclopedic Medical Dictionary, 2005). 
Operational: Males between the ages of 9-21 who received care at three clinics located 
in the southeastern United States. 
Parent 
Theoretical: Caretaker/guardian of a child (Taber's Cyclopedic Medical Dictionary, 
2005). 
Operational: The caretakers of patients who received care at three clinics located in the 
southeastern United States 
Centers for Disease Control and Prevention (CDC) guidelines for HPV 
Theoretical: The national public health institute for the United States (CDC, 2012). 




Theoretical: A three-dose series vaccine to help protect against the human 
papillomavirus (CDC, 2012). 
Operational: Gardasil ® (human papillomavirus quadrivalent), a three-dose series 
vaccine, to help protect males against the human papillomavirus. 
Assumptions 
The HPV vaccine has been available to girls and boys for several years. The assumption 
was made by our research group that the HPV vaccine was offered in all clinics to boys, ages 9-
21. The assumption that health care providers educated patients on the importance of receiving 
the HPV vaccine was also assumed by our group. The assumption that health care providers 
educated parents on the importance of their son receiving the HPV vaccine was also assumed by 
researchers. 
Limitations 
Several limitations were discovered during our research project. Missing documentation 
in the charts on rather education was provided to the patient limited the data collected. Another 
limitation was the expense of the HPV vaccine. Some patients were not able to afford the 
vaccine. Some clinics did not offer the vaccine to patients because of the expense for the clinic. 
Researchers had to look through paper charts to collect information which made data collection 
timelier. 
Summary 
HPV is defined as the leading cause of STI's in the United States (CDC, 2012). The 
CDC (2012) recommends boys along with girls should receive the HPV vaccine. Our research 
was to determine if boys, ages 9-21, were vaccinated by their health care provider and if patients 
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and their parents received education on the importance of the HPV vaccine. The background 
information regarding the importance and significance of receiving the HPV vaccine was 
provided in this chapter. In addition, the purpose, the significance, and the specific research 
questions were presented. 
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Chapter II 
Review of Literature 
The CDC (2012) stated that, "Human papillomavirus (HPV) was the most common 
sexually transmitted disease (STD) in the United States and infected approximately 50% of 
sexually active males and females" (p.39). The human papilloma virus (HPV) was associated 
with cervical cancer since Harald zur Hausen confirmed the presence of HPV-DNA in biopsies 
of cervical cancer in 1983 (Press Release, 2008). In 2006, the Food and Drug Administration 
(FDA) approved two vaccines to prevent HPV infections: Gardasil® and Cervarix (Gunther et 
ah, 2008). These HPV vaccines were subsequently proven safe and effective through several 
clinical trials. In an attempt to decrease the rate of infection, in 2006 the CDC suggested that 
girls, aged 13-26, be vaccinated. In 2009, the CDC suggested that boys, aged 9-21, be 
vaccinated with the human papillomavirus quadrivalent. The CDC and the medical community 
hoped that education about HPV and the acceptance of the HPV vaccine would result in 
markedly reduced HPV related cancers in the future. 
Theoretical Framework 
By promoting health through prevention and increasing the client's "level of well-being" 
as they interact with their environment, Nola Pender believed that a client's need for "a positive 
dynamic state not merely the absence of disease" was the most constant goal of health promotion 
("Model," 2012). Nola Pender and her husband sought to prove that health care providers could 
have a positive influence on their patient's behaviors (Pender & Pender, 1980). The current 
research study utilized Nola Pender's health promotion model (HPM) as the theoretical 
framework. 
Using Pender's health promotion model guided our research to focus on the need for 
promoting healthy behaviors such as receiving the HPV vaccine. Health-promoting behavior 
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was not practiced by everyone and this information was revealed by our research. The purpose 
of our research was to determine if males, age 9-21, received the HPV vaccine and if they or 
their parents received education on the CDC's recommendations for the HPV vaccine. 
Pender & Pender (1980) conducted a survey in a small Illinois county which included 
388 people who were asked if they would use the services of a nurse practitioner who could 
provide prevention and health promotion care. Over 61% said that they would be open to using 
such services. The participants looked forward to accessing the education and counseling that 
would be provided by nurse practitioners. The people in this study wanted access to health 
promotion services. These people stated that they intended to utilize those services as soon as 
they arrived, proving what Nola Pender theorized. Pender theorized, people seek better health 
and will make good choices when given the opportunity (Pender & Pender, 1980). 
Nola Pender believed people would actively seek opportunities and tools which help 
them lead a healthier and more fulfilling life. Our research group demonstrated that those 
opportunities and tools as described by Pender were not being provided at an acceptable rate in 
regard to vaccinating boys against HPV. 
Related Research 
Education and Motivation Towards Accepting Vaccination. Cates et al. (2012) 
conducted a study which included qualitative and quantitative data on parents' knowledge and 
perceptions of the HPV vaccine and the kinds of messages that helped to motivate parents in 
vaccinating their pre-teenaged sons. Five focus groups, consisting of 29 black parents of 11-12 
year old boys, were picked from local churches and a middle school in North Carolina. A group 
of 100 racially diverse parents of 9-13 year old boys were chosen from a university-based health 
clinic. Parents were asked about their beliefs regarding HPV and how severe the virus is related 
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to STD and cancer risk. Parents were also questioned about the importance of the HPV vaccine 
and about any concerns related to the cost, safety or access to the vaccine. The purpose of the 
study was to reveal what motivates parents to vaccinate their sons with the HPV vaccine and 
how they felt about the different types of messages that promote the HPV vaccine. Chi-square 
and t tests analyses of variance were used to determine the differences in quantitative data and 
comparison methods were used to determine the differences in qualitative data (Cates et ah, 
2012). 
In the first part of the qualitative research, parents were questioned on their thoughts 
about how HPV affected their sons and were asked for feedback about how to encourage parents 
to vaccinate their sons. Questions asked among the focus groups included: "Do you think boys 
are at risk for HPV infection?" "Do you know where to go to get the vaccine and how much it 
costs?" (Cates et ah, 2012, p. 40). At the end of the meeting, parents were asked to write down a 
message they thought would encourage parents to get their sons vaccinated. Nine messages were 
picked and the next focus group was asked to provide feedback concerning the design concepts 
derived from those nine messages. 
Different message designs were conducted including illustrations and text. The group 
also picked important facts to include in the interview for the following focus group. During the 
interview, parents were asked if they had ever heard of HPV vaccine for boys and if they would 
vaccinate their sons (Cates et ah, 2012). Parents were also asked about which design influenced 
them to vaccinate their sons and to provide feedback on what would encourage them to vaccinate 
their son. The interview concluded with a questionnaire for the parents to rate the HPV facts in 
regard to the likelihood of vaccinating their son. 
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Researchers used constant comparative methods including Atlas.ti, to code the different 
categories based on the interview guide questions, the health belief model and social marketing 
principles. Chi-square tests were also used to assess the differences among parents including 
their age, sex, race and likelihood of vaccination. Mean scores were calculated from how 
motivating the statements about HPV were and a sample t test of variance was used to compare 
the mean across the subgroups (Cates et al., 2012). 
Results suggested that parents did not know much about HPV in males. Concerns 
revealed from the research included: low awareness of HPV disease, low awareness of HPV 
vaccine, benefits of HPV vaccine, barriers to HPV vaccine, self-efficacy and sources they can 
trust (Cates et al., 2012). In the interviews conducted, before the posters with the messages 
about HPV were shown, 11% of parents had heard about HPV vaccine for males, 6% indicated 
that their sons had received one dose, 61% said they would or probably would vaccinate their 
sons, 16% said they probably would not and 23% were unsure if they would. After the posters 
were shown and parents picked which one was the most motivating to them, 47% said they 
would talk to their health care provider about vaccination for their sons. The poster chosen 
focused on prevalence and possible consequences of HPV infection. The messages that 
motivated parents the most to get their sons vaccinated for HPV focused on risk of infection and 
contained images of parents with their sons (Cates et al., 2012). 
Strengths of the study were the systematic design and testing of HPV vaccine messages 
with parents of boys who were 11-12 because of the small sample size and also because 11-12 
year olds receive the most effectiveness from the vaccine (Cates et al., 2012). The selection of 
different races, age and gender was also beneficial in receiving different feedback. However, 
one of the limitations of the study was selecting interviewers at a clinic because these parents are 
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already seeking healthcare and are more likely to be involved in vaccination programs. 
Improvement of the study was done by comparing responses from parents who already sought 
healthcare for their sons verses parents who did not seek healthcare. 
This study was significant in determining the number of parents who are unaware of the 
HPV vaccine and especially unaware of the availability of the vaccine for boys. Parents also 
were unaware that males served in preventing spread of the HPV virus which in turn decreased 
female risks of cervical cancer. The HPV vaccine also decreased the risk of genital warts in both 
males and females (CDC, 2012). The results of this study were beneficial in our research to 
determine if males were receiving HPV vaccines or receiving information about the importance 
of HPV vaccine. 
In the 1980's, several scientists worked independently on what would eventually be 
marketed as Gardasil® by Merck and Glaxo (McNeil Jr., 2006). In 2006, the Centers for 
Disease Control suggested the vaccine be offered to females aged 13-26. In 2009, they made the 
same recommendation for males, aged 9-21. Only a few studies were conducted which showed 
the differences in the male and female vaccination rates. One such study was conducted in North 
Carolina beginning in 2010, by Gilkey, Moss, McRee, & Brewer (2012) and revealed the poor 
vaccination rates among boys of target age range. 
Once their sample selection was made, Gilkey et al. (2012), conducted a mixed data 
analysis using the quantitative bivariate (yes/no) question, "Has your child had any shots of the 
HPV vaccine?" Interviewers then used a mixed data set (both quantitative and qualitative) 
questions including inquiries about age, employment status, status of other immunizations and 
school type. The data set helped in later defining conclusions as to why the vaccine may or may 
not have been offered to the subjects or declined by the subjects (Gilkey et al., 2012). 
1 3  
Surveyors wanted to know if the newly developed HPV vaccine was successfully being 
administered to all those eligible, particularly boys. The surveyors also wanted to discover any 
correlate differences between the two sexes if the vaccine rates differed. Therefore, the research 
question for this review was the same as the title: "Do correlates of HPV vaccine initiation differ 
between adolescent boys and girls?" (Gilkey et ah, 2012, p. 5928). 
Since the HPV vaccine was only available to boys from 2009, any subsequent studies 
were conducted after that date. The majority of the 30 articles cited by the author were published 
in 2011. Since so few studies existed regarding the delivery of HPV vaccinations in children, the 
researchers created their own conceptual framework by linking the information in several articles 
to determine their research question. Therefore, they created a theoretical framework for others 
to use in the future. 
A survey method was used in this research. The data collected was gleaned from a 
random-digital-dialed, population based survey conducted in North Carolina in 2010 called the 
"Behavior Risk Factor Surveillance System" (BRFSS) survey which contained 20,208 
respondents. From this master survey, parents were asked if there were any children younger 
than 18 years of age living in the house, in which case they become eligible to participate in the 
"Child Health Assessment and Monitoring Program" (CHAMP) survey. Survey software 
randomly chose an 'index' child within each qualifying household. Because the researchers 
chose to focus their study on those children falling within the age range of 11-17, all index 
children outside the age range were elliminated leaving 3,174 eligible participants. The parents 
of 2,009 of these eligible participants returned the survey. The group was further decreased by 
eliminating children whose parents had never heard of the HPV vaccine, those whose parents 
had declined to answer, or those whose parents were unsure if their child had ever received the 
14 
vaccine at all. The final total number of participants was 751: 359 male index children and 392 
female index children (Gilkey et al., 2012). 
Since the study was conducted through phone interviews after an initial bivariate inquiry 
with no name identification for the index child, privacy protection was a minimal hazard. Bias 
was avoided through use of randomization software and elimination requirements. The 
researchers used a descriptive/statistical research design to discover associations between their 
established variables and to attempt to describe why such low rates of HPV vaccination were 
occurring ("Descriptive Research," 2012). 
The researchers performed a one-time study using data collected from a yearly survey 
performed in 2010 by the state of North Carolina. Follow-up calls completing the study were 
conducted after the aforementioned eliminations were made to determine the target group. There 
was a mix of data collection over the course of the study, primarily using data already collected 
through one agency, then returning once the sample selection was established for a single phone 
interview. 
The population was drawn from two state-wide surveys performed yearly in North 
Carolina: the Behavioral Risk Factor Surveillance System (BRFSS) survey and the Child Health 
Assessment and Monitoring Program (CHAMP) survey. If, during the BRFSS survey, the 
responding adult (who'd been previously selected by random phone dialing) answered that there 
was a child under that age of 18 in the household, that household was pulled into the CHAMP 
survey. From that pool, survey software chose one index child. The final sample selection was 
narrowed to only those boys and girls aged 11-17 years, whose parents had heard of the HPV 
vaccine and were sure of their child's vaccination status (Gilkey et al., 2012, p. 5929). 
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The researchers based their data collection on the three surveys: BRFSS, CHAMP and 
the follow up phone calls they made themselves. They applied a "logistic regression" (Gilkey et 
al., 2012, p. 5929) model to analyze the boys and girls separately. Statistical analysis software 
was also used to report "unweighted frequencies, weighted proportions, odds ratios, and 
confidence intervals" (Gilkey et al., 2012, p. 5929) to the results. 
The researchers used Stata Version analysis software that delivered a critical alpha of 
0.05 which means the confidence level was high enough in this two-tailed test to reject the null 
hypothesis. They reported unweighted frequencies, weighted proportions, odds ratios and 
confidence intervals to increase the validity of the results (Gilkey et al., 2012). The study 
revealed that many factors are lacking in regards to the HPV vaccination of boys, ages 9-26: 
education, opportunity and additional research to name a few. Parents, who did not receive 
education about the importance of the HPV vaccine, would have no reason to ask for the vaccine. 
If parents were educated about the dangers of contracting the HPV virus, more children would 
likely be vaccinated leading to a decrease in infection rates. If more clinics made it part of their 
daily practice to offer the vaccine to those who qualify, the rates of HPV infection would 
consequently fall. The significance of "not knowing" to seek a vaccination was a cornerstone of 
both our research and this study and carried much weight as to the argument that education and 
opportunity were critical for the success of medical interventions. 
The strength of the study was in its data collection: randomized sampling. Random 
sampling by design included subjects by chance decreasing the likelihood of bias. While 
samples chosen by chance may not be representative of the whole: the larger the pool of subjects 
increases the likelihood of the usefulness of the sample. Researchers used randomly selected 
participants with reducing stratifiers before the experiment: households with children, randomly 
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chosen index children, boys age 9-21, and parents who knew the immunization history of their 
children. By using reducing tools like stratified random sampling, confidence in the final data 
pool remained high (Polit & Beck, 2012). 
The weakness of the study fell to the single data collection season. A one-time collection 
of data did not show progress or regression in any one direction. Performing several like studies 
over the course of time showed population, age and geographical trends, thereby strengthening 
the study set. While researchers were able to derive several additional findings, the study did 
point out that only 14% of the reporting parents revealed their sons had received the HPV 
vaccine compared to 44% of parents with daughters. Vaccination levels were highest among 
older boys and those from families earning less than $50,000 a year and who had also been 
vaccinated for other diseases such as influenza at the same time (Gilkey et al., 2012). 
In order to improve the vaccination rate of boys in North Carolina, the researchers 
suggested that the HPV vaccine be offered at the same time other optional or required vaccines 
were given. They surmised that educating health care workers toward this approach would 
logically increase the acceptance rate of the vaccine. This approach was the simplest since 
vaccine programs were already in place and the HPV vaccine could be offered alongside the 
already established vaccines (Gilkey et al., 2012). 
This study confirmed that boys were not receiving the HPV vaccine at the same rate as 
girls. With so few studies concerning this subject in existence, this evidence was conclusive and 
important. When considering how the researchers obtained the final sampling (by starting with a 
state-wide random sampling) the conclusion logically carried more weight in that repeatability in 
other states using the same collection and analysis technique also proved to be valuable and 
reflective of practices in those subsequent states. 
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Determining the Length of Immunity and How It Will Affect the Future. Based on 
lifetime natural immunity that developed when exposed to the HPV virus through physical 
contact, the vaccine delivers lifetime immunity without the recipient ever having developed an 
HPV infection. Gunther et al. (2008), created several scenarios which demonstrated what could 
happen in the future regarding the prevalence of cervical cancer as it relates to the presence of 
the virus. 
The researchers chose a "deterministic compartmental model" which involved "varied 
natural history and intervention strategies, along with comprehensive sensitivity analyses to 
compensate for uncertainty in parameter estimates" (Gunther et al., 2008, p. 1654). Researchers 
were able to graph different scenarios in order to examine, through 2055, possible trends that 
occurred depending on whether a person contracted HPV and became infected (and developed a 
lifelong immunity), whether they were vaccinated and developed a lifelong immunity or whether 
they were vaccinated and developed only ten year immunity. Based on these three scenarios, the 
researchers were able to make reliable predictions about the future prevalence of HPV in the 
current vaccine eligible population (Gunther et al., 2008, p. 1653). 
The researchers were concerned that vaccinating certain age groups might later cause an 
increase in HPV prevalence after immunity wears off. This information was based on what is 
currently known about the duration of immunity for some vaccines: some create lifelong 
immunities while others last only a certain amount of time. Because the HPV vaccine was not 
available long enough to ascertain its longevity, researchers were unsure as to whether or not a 
'booster' vaccine will be required later in life to prolong immunity. 
The conceptual framework of this study used mathematical modeling to produce several 
different scenarios to predict the future prevalence of HPV infections. Since mathematical 
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modeling was the only method used in this research and no human participants were used, there 
was no possibility of infringing on human rights. Mathematical modeling provided no bias since 
there were not any participants. 
By using a deterministic compartmental model, which was the simplest way to 
extrapolate the conduct of infectious diseases, the researchers were able to produce succinct and 
dependable results. Using a deterministic compartmental model allowed researchers to assume 
that humans as a population are heterogeneous and that the only difference for research puiposes 
is the presence or absence of degree of the focus disease. The mathematicians were to focus 
strictly on producing the needed curve (Chitnis, 2011). The statistics were run several times, 
adding in sub-compartments and performing sensitivity analyses as they went to narrow the 
outcome to more usable information. 
The population was a set of model prospective defined at the onset of the experiment. 
Researchers labeled compartments as follows: "susceptible, S; exposed, E; infectious without 
lesions, /; infectious with low-grade SIL (L-SIL), L; infectious with high-grade SIL (H-SIL), II: 
immune, M; and cancer C. With the exception of L, H, and C, similar compartments were used 
for males (Gunther et al., 2008, p. 1654). Once the compartments were defined, the 
extrapolation program was able to mathematically determine thirty years of infection rates based 
on lifetime immunity versus ten year immunity. Collection was through mathematical 
extrapolation of modeled scenarios, measured by the same program and shown in graphs and 
statistics after several scenarios, corrections and sensitivity analysis were performed. 
Statistically, modeling and the equations written for corresponding compartments were 
simple and accurate ways to graph suspected scenarios. The equation for each compartment 
graphed the 'question' and by comparing several graphs/compartments against one another, 
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researchers were able to visualize and interpret what those results meant. In this model, the 
strength lied in the mathematical equations and graphs, making the strength high. The weakness 
for the experiment overall was in not knowing the length of immunity created by the HPV 
vaccine. Retroactively, this changed much of the graphed conclusions, if and when the 
assumptions made on the front end of the experiment are changed in the future by a more 
accurate understanding of the HPV vaccine's strength. 
Researchers determined that if the HPV vaccine delivered a lifelong immunity, cervical 
cancer would decrease significantly over the next 50 years (especially in those vaccinated at an 
early age as opposed to those vaccinated at a later age). Research also showed that if there was 
only a ten year immunity, a rebound would occurr around 2030 when highly sexual twenty-
something's immunities wore away if they had not been re-vaccinated. In this scenario, the 
cervical cancer rate eventually rose in time to levels of those who were never vaccinated 
(Gunther et al., 2008, p. 1655). 
By using reliable mathematical models, the researchers were allowed to see the profound 
potential of HPV vaccines on the cervical cancer rates of the future. Through extrapolation, 
science painted a picture of what the horizon might look like if a wide, blanketing vaccination 
plan were successful. Lives would be saved and lengthened in the best case scenarios, and lost 
or shortened if no action is taken at all. The scenarios illustrated through mathematical models 
information were as valuable to the future of cancer research as perhaps any to date, because of 
the millions of lives which were affected. 
The most significant information researchers found was the importance of determining 
the length of immunity created by the HPV vaccine. This determination drove the future 
vaccination policies concerning HPV and in turn maximized its effectiveness, most notably, a 
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significant decline in cervical cancers. This research showed that what was being done today in 
clinical sites could really affect future cervical cancer rates. The more children (both boys and 
girls) who were vaccinated over the next two or three decades could radically decrease the rate of 
cervical cancer among women. 
The Safety and Side Effects of the HPV Vaccine. The human papillomavirus (HPV) 
vaccine was proven to be safe and effective based on several clinical trials. Pomfret, Gagnon & 
Gilchrist (2011) used several medical databases and websites, including the Centers for Disease 
Control and Prevention, from 1996-2009 to conduct their research. The clinical trials included in 
the article used quantitative research to determine the safety and effectiveness of the HPV 
vaccine. The first clinical trials discussed were to determine how safe the HPV vaccine was 
when administered to different participants. The article did not mention if the participants were 
offered any reward for participation. 
By December 2008, more than 23 million doses of HPV vaccine were administered in the 
United States. Based on reports from the Vaccine Adverse Event Reporting System (VAERS), 
only 11,916 cases of adverse effects were reported. The adverse effects reported were syncope, 
pain or redness at injection site, nausea and headache (CDC, 2012). This number seemed high 
but only 6% of the cases were serious. Headache, pain at injection site and fainting were some 
of the mild effects reported. Guillain-Barre Syndrome (GBS), blood clots, shock and death were 
the serious complications reported. Only 10 cases of GBS were confirmed (Pomfret et al., 
2011). 
Pomfret et al. (2011) discussed a clinical trial which was performed to determine if an 
effect existed between the participants' baseline characteristics and vaccine-induced response. 
The quantitative study included 12,343 patients ranging from age 9-15. The patients chosen for 
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the study were virginal boys and girls. The HPV vaccine was administered in a 3-dose series of 
intramuscular injections. The second injection was given two months after the first and the third 
was given six months after the first dose. During this clinical trial, 96% of the patients received 
the 3-dose series of vaccines. The trial revealed that at month 7, the geometric mean titers 
(GMTs) decreased as the age at the first vaccination increased. The results were influenced by 
race, ethnicity, body mass, birth control use, geographical region and lactation status. The 
outcome of the trial revealed that the HPV vaccine was 100% effective when given to patients, 
ages 16-26 (Giuliano et al., 2007). 
A trial of 1,781 males and females, ages 9-15, was conducted to assess the tolerability 
and immunogenicity through 18 months after enrollment. The trial also was conducted to assess 
the immune response among preadolescent and adolescent males and females through anti-HPV 
geometric mean titers (GMTs) and seroconversion rates at the 7th month. The immunogenicity 
of males and females was compared through a non-inferiority analysis for each of the HPV types 
(6, 11, 16, and 18). The comparison was done between the per-protocol populations, 948, 949, 
944 and 952 patients. The results concluded that for each HPV type, more than 99.5% of 
patients had seroconverted at month 7. Males had higher GMTs for all HPV types. There was a 
fold difference (males divided by females) in GMT parameters for all 4 HPV types: (1:3, 95%, 
1:1 & P<0.001), (1:1, 95%, 0.9:1.4, P<0.001), (1:4, 95%, 1.1:1.8, P<0.001), (1:5, 95%, 1.2:1.9, 
P0.001). The numerical results concluded that the anti-HPV GMTs in males were non-inferior 
to females during the study. The immunogenicity, after 18 months and three doses, revealed that 
>91.5% of all patients were seropositive. The values after 18 months and three doses were 4-7 
times lower than the values after 7 months. Patients receiving the vaccine reported pain, redness 
and swelling at the injection site. Those who received the placebo did not experience problems 
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at the injection site. Adverse effects (n=5) were reported by patients who received the vaccine. 
The adverse effects did not seem to be related to the actual vaccine (Reisinger et al., 2007). 
According to Pomfret et al. (2011), the HPV vaccine was safe to be administered to 
patients and effective in preventing pre-cancerous lesions. The side effects reported were not life 
threatening. Based on side effects alone for HPV. patients felt safe about receiving the vaccine. 
The significance of this research was that it was demonstrated that the benefits of the HPV 
vaccine outweighed the side effects. 
The information received from this research was significant because the information was 
used in our research project to educate health care providers, patients and parents. The statistics 
given in the article were a major strength not only to the reader but to parents and patients to help 
persuade their decision making. HPV vaccine like other vaccines was a preventive, self-
promoting health strategy. Males needed to be vaccinated with HPV along with females. 
According to the findings in this article, males benefited as much as females from the HPV 
vaccine. Vaccinated males helped to lower the spread of HPV and genital lesions (CDC, 2012). 
With more research being conducted, the vaccine may eventually be approved to cover a broader 
range of age groups. Barriers to the vaccine and the article are the limited age groups. Gender, 
race and ethnicity do not cause any barrier to HPV vaccination or research. If the age range of 
vaccination was expanded, less people would be affected by HPV. 
Efficacy of the Vaccine. Human Papillomavirus (HPV) infected the squamous 
epithelium in both sexes, leading to anogenital condylomata acuminate. In males, HPV leads to 
cancers of the penis, anus, and oropharynx (Reisinger et al., 2007). The rate of genital HPV 
infections among males was similar to that in females. However, there were differences between 
the sexes in the immune response to HPV. The lower immune response to natural infection in 
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males partially explained the higher prevalence of HPV infections as compared with the 
prevalence among females, and the constant prevalence and incidence of HPV infection across a 
wide age range in male. Given the prevalence of the disease in the male population, a study was 
conducted to determine the efficacy of the quadrivalent HPV vaccine against anogenital infection 
and external genital lesions associated with HPV-6, 11. 16, or 18 in boys and men between the 
ages of 16 and 26 years. 
This quantitative study performed by Reisinger et al. (2007) was conducted on 3,463 
heterosexual boys and males ages 16 to 26 and 602 homosexual boys and males ages 16 to 26. 
Of the 4,065 participants enrolled, 2,032 were randomly assigned to the vaccine group and 2033 
were randomly assigned to the placebo group. These study groups were balanced with respect to 
age, race or ethnic group, region, smoking status, circumcision status, and sexual history. All the 
participants were tested for HPV DNA to identify subjects who acquired new HPV infections 
during the study. The design of the study included administering the HPV vaccine or placebo on 
day 1, month 2, and month 6 to randomly assigned subjects. The participants were required to 
record any systemic adverse events and all serious adverse events that occurred on days 1 
through 15 after receiving each dose. The participants' anogenital areas were examined on day 1 
and at months 7, 12, 18, 24, 30, and 36. Any suspicions lesions were biopsied by the examiner 
to determine whether or not the lesion was HPV associated. 
The study illustrated the effectiveness of the HPV vaccine when administered to the male 
population. In the intention to treat population, efficacy in preventing the development of any 
external genital lesion, regardless of HPV type, was 60.2 % (Giuliano, 2011). In the per-protocol 
population, the vaccine reduced the incidence of external genital lesions related to HPV-6, 11, 
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16, or 18 by 90.4%. Efficacy against condylomata acuminata in the per-protocol population was 
89.4% (Giuliano, 2011). 
Strengths of the study illustrated the importance of the efficacy of the quadrivalent HPV 
vaccine in preventing HPV infection and related diseases in men. Condylomata acuminata, the 
most common HPV-related lesion, was associated with substantial physical and psychological 
morbidity and has a high rate of treatment failure, and treatment of recurrent episodes is costly 
(Giuliano, 2011). 
The statistical data included a substantial number of participants over a broad period of 
time. Some who did not return for their scheduled examination during the study time period 
were automatically excluded from the study. Researchers examined the participants at given 
time periods and any participant in the study who tested positive for HPV or had lesions to the 
anogenital area that were even questionable, were automatically dismissed from the study. The 
study results were provided in detail on graphs showing the results of the test during each month 
that the participants were to return for scheduled exams. 
Weaknesses of the study included adverse events some investigators believed to be 
associated with the vaccine or the study procedure and all deaths were recorded during the entire 
study period. This research was used to illustrate the effectiveness of the vaccine once 
administered to the target population. This research, with the information provided on the 
impact it has on HPV, was helpful also to sway doubtful people towards getting vaccinated with 
the HPV vaccine. 
Anogenital Human Papillomavirus (HPV) infection was the most common viral infection 
of the anogenital tract worldwide; with cumulative lifetime risk for infection approaching 70% 
(Reisinger et al., 2007). Worldwide, more than 500,000 cases of cervical and other genital 
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cancers were caused by HPV infection annually with more than 273,000 deaths attributable to 
cervical cancer (Reisinger et al., 2007). The HPV family included approximately 100 types, 35-
40 which infected the epithelium of the anogenital tract. However, only a subgroup of HPV 
types caused dysplasia that led to cancer. HPV types 16 and 18 caused approximately 70 % of 
cervical and other HPV-related genital cancers. HPV types 6 and 11 caused approximately 90% 
of all cases of classic condyloma acuminate. This literature illustrated the effectiveness of the 
quadrivalent HPV (types 6, 11, 16, and 18) vaccine in women aged 16-26 years old. According 
to studies of this vaccine, more than 12,000 women aged 16-26 years, experienced robust 
immune responses, leading up to 100% prevention of HPV 16 and HPV 18 related cervical 
intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ and pre-or noninvasive cervical 
cancer, compared with placebo (Reisinger et al., 2007). 
A study performed by Reisinger et al. (2007) was a quantitative study that focused on 
whether or not the responses of the HPV vaccine seen in 16-23 year old females are comparable 
to responses seen in 10-15 year old girls and also 10-15 year old boys. This quantitative study 
began with enlisting 61 various clinical sites worldwide, and enrolled three distinct populations: 
10-15 year old girls, 10-15 year old boys, and 16-23 year old females, with a total of 
approximately 500 participants in each study cohort. The study's design was to compare the 
immune response to each HPV type after a three injection regimen of a full dose of a 
quadrivalent HPV vaccine through month seven. Serum samples were obtained at day one, at 
month three, and at month seven in all participants. The Anti-HPV levels were determined using 
an HPV type-specific competitive Tuminex xMAP-based immunoassay. According to the 
results of the geometric mean titers, results were robust by one month post dose in all three 
groups. By month seven, seroconversion rates were equal to or even greater than 99% for all 
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four human papilloma virus types in each group. This was consistent with the higher 
immunogenicity response that was observed in girls and boys than in women at month seven 
(Block, et ah, 2006). Results allowed the bridging efficiency of benefit of vaccination of boys as 
well as girls based on the results of testing. 
The study's significance illustrated how administration of the HPV vaccine, not only to 
women, but to adolescent boys and girls, improved geometric mean titers amongst each group. 
The study also illustrated the low incidence of adverse reactions associated with the 
administration of the HPV vaccine, which included mild fevers and occasional mild stomach 
discomforts. Strengths of the study included the overall design of the study and the diverse 
population that included more than 500 participants over a two year period. Weaknesses 
included age of the population and the requirements of participants to utilize contraceptives or 
remain abstinent for this study. The study never illustrated how compliance of this variable was 
obtained. 
Significance to this study was that the information obtained from this study would allow 
us to educate families in the future about how the HPV vaccine was just as effective in boys as it 
was in girls. This literature was also useful in determining the effectiveness of the vaccine. 
Cost Effectiveness versus Necessity. Persistent infections with high risk oncogenic type 
HPV were associated with causing cervical cancers in females. According to the literature, two 
types, HPV 16 and HPV 18 were responsible for about 70 percent of the cases of cervical cancer 
worldwide and contribute to over 80 percent of anal cancers, 30 percent of vulvar, vaginal, and 
oropharyngeal caners, and 20 percent of oral cancers (Kim, 2009). Two types of low risk non-
oncogenic types, HPV 6 and HPV 11, were associated with most cases of anogenital warts and 
juvenile onset recurrent respiratory papillomatosis (Kim, 2009). HPV was a sexually transmitted 
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infection that was transmitted from male to females; vaccinating boys led not only to direct 
health benefits for themselves but also to indirect health benefits through reduced transmissions 
of HPV. The purpose of this study was to determine whether vaccination of boys with HPV 
vaccine along with females is cost effective. 
The study began by using a quantitative approach to determine the cost effectiveness 
associated with the administration of HPV vaccine to the boys along with girls. The study's 
conclusion stated that "Given the information currently available, our analysis favors HPV 
vaccination of preadolescent girls (with continued screening in adulthood) as valuable 
intervention for its cost, consistent with findings from other cost effectiveness studies (Brisson et 
al., 2011). Including boys in the vaccination program generally exceeded conventional 
thresholds of good value for money. The article then proceeded to describe how the conclusion 
was derived by describing disease simulation models which are calibrated to fit empirical data. 
The data was used to develop the best available data, compare health and economic outcomes of 
using different interventions, and explore "what if' scenarios that would otherwise be unfeasible 
or unethical to pursue in a clinical study. The type of model used was a dynamic model in that it 
was aged structured, population based model that simulates multiple birth cohorts of females and 
males from birth until death. The model was based on aging and how males and females develop 
relationships as they age and the patterns of sexual behavior in the US. Age of the participant 
was taken into consideration when calculating the probabilities of transmitting HPV to partners. 
The model also took into consideration the increased immune response of females after clearance 
of a previous exposure of HPV due to the development of natural immunity. 
One of the weaknesses of this study was that it used simulations models synthesizing 
epidemiological, clinical, and economic data to evaluate the cost effectiveness of including boys 
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in a routine HPV vaccination program along with preadolescent girls. According to the British 
Medical Journal, the most important health benefits from HPV vaccination of adolescents (that is 
the prevention of cancer) would not be observed for years, possibly decades (Brisson et al., 
2011). Statistical significance was being undermined by the conclusion that routinely vaccinating 
boys along with girls is not cost effective. The issue of whether or not something was cost 
effective should be of no concern if there was a proven vaccine available with the potential to 
prevent exposure to genital warts. 
Brisson et al. (2011) sited the knowledge and use of herd immunity as a deciding 
economic factor in the failure or success of new vaccines. Herd immunity was the primary goal 
of immunization efforts. Herd immunity resulted from calculated vaccination of a certain 
percentage of a population with the intent of preventing spread of the disease by minimizing the 
number of people left susceptible to the disease, thus protecting the 'herd' from infection. 
Historically, this approach all but eradicated some diseases such as polio and small pocks. 
Because of parents' changing attitudes toward immunizations leading to a decrease in 
vaccination rates, diseases such as measles and pertussis had alarming increases ("Herd 
Immunity," 2012). 
The Human Papillomavirus vaccine (HPV), a sexually transmitted virus linked to 
cervical, genital and mouth cancers that occurred years after initial infection, was first offered to 
girls, ages 13-26, in 2006. Assuming that increased vaccination rates increased the herd 
immunity affect and therefore decreased the later development of cervical cancer, the CDC 
suggested in 2009 that the vaccine be offered to boys; age 9-21 (Gilkey, Moss, McRee, & 
Brewer, 2012). In their article, "Incremental Impact of Adding Boys to Current Human 
Papillomavirus Vaccination Programs: Role of Herd Immunity," researchers Brisson et al. 
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(2011) questioned the economical aspect of vaccinating boys who would otherwise be protected 
from infection through the herd immunity dynamic. This article reviewed the research reported 
and discussed the impact of its results on our group's study concerning the HPV vaccination 
rates in selected communities in the mid-south. 
The researchers used a mathematical modeling program with an "individual-based 
transmission-dynamic model" (Brisson et al., 2011). The modeling was used to extrapolate data 
out seventy years from vaccination. Researchers attempted to determine if vaccinating boys 
along with girls decreased the rate of cancer enough to justify the economic investment required 
to vaccinate the second half of the population. The researchers were concerned that vaccinating 
only girls might not create the herd immunity needed to protect the population from infection 
and later from HPV associated cancers. Alternately, they wondered if vaccinating boys might 
amount to "over vaccinating" the population which would in terms of economic loss, be reflected 
as a decline in incremental impact (Brisson et al., 2011). The critical cross-over point at which 
vaccination effectiveness decreased incrementally was due to cost that researchers were hoping 
to find. 
The idea of herd immunity was ultimately to manage the disease effectively by reducing 
the numbers of those susceptible. Assuming that some people should still be infected, by 
predicting the future equilibrium of infection rates and vaccinating just enough people to 
maintain the equilibrium, the vaccination program was at once effective and economical. Three 
of the fifteen articles used by the researchers were outdated, but each only by one or two years. 
The conceptual framework used mathematical modeling to produce several different scenarios 
showing the effectiveness of vaccinating only girls compared to vaccinating boys and girls 
together. The researchers used "individual-based transmission-dynamic modeling" of forty-four 
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parameter sets to develop their conclusions (Brisson et al., 2011). Since mathematical modeling 
was the only method used in this research and no human participants were used, there was no 
possibility of infringing on human rights. Mathematical modeling provided no bias since there 
were no participants. 
Researchers used individual-based transmission-dynamic models to simulate conditions 
associated with the vaccination rate. The individual-based section of the model tracked or 
predicted what individuals did over a period of time based on certain characteristics and 
behaviors, then extrapolates those results out into a larger, more global population (Reynolds, 
1999). This study used an individual-based population that was "heterosexual, open and stable" 
(Brisson et al., 2011). They assumed vaccination would occur before participants became 
sexually active and eliminated that variant. They applied several behaviors as parameter sets 
including gender, high and low sexual activity rates, and a range in numbers of sexual partners to 
this model (Brisson et al., 2011). 
The transmission-dynamic model portion of the study was meant to "reproduce the direct 
and indirect effect that may arise from a communicable disease control program" (Transmission 
Modeling, n.d.). In other words, the program was able to predict the spread of communicable 
diseases in certain circumstances: in this case by preset parameters. When researches merged 
forty-four parameter sets within the two predictive models they were able to obtain the data they 
sought. Though the study was conducted one time, the statistics were run several times, each 
time adding new information through varied data sets and scenarios. Ultimately forty-four 
parameter sets modeled the predictions. 
The population was a set of model prospective defined at the onset of the experiment. 
Through the individual-based model, researchers changed scenarios by introducing different age 
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ranges, applying two gender models, increasing the number of sexual partners and increasing the 
number of sexual encounters. Through the transmission-model, researchers changed the type of 
HPV virus that was transmitted, modeling eighteen different HPV types within the forty-four 
parameter sets (Brisson et al., 2011). Collection was through mathematical extrapolation of 
modeled scenarios, measured by the same program and shown in graphs and statistics after 
several scenarios. The graphing of the bivariate parameters produced outcomes for each of the 
forty-four parameter sets which researchers then averaged to get overall outcome hypotheses. 
Statistically, modeling and the equations written for corresponding parameters were simple and 
accurate ways to graph suspected scenarios. The equation for each parameter graphed the 
'"question" and by comparing several parameters against one another, researchers were able to 
visualize and interpret what those results meant and predict outcomes. 
In this model, the strength was in reliability of mathematical equations and graphs, 
making the strength high. The overall weakness for the experiment was in the almost limitless 
number of scenarios that could be played out. Although the individual scenarios were 
meaningful, the sheer volume of information could potentially weigh down the conclusion and 
the availability of a few practical applications. 
Researchers determined that at some point in the effort to protect the public from HPV 
infection, there was a cross-over point where the effectiveness of the herd immunity was no 
longer increasing. If girls were vaccinated at a high rate and early enough, high rates of HPV 
protection occurred. Since girls were protected from HPV, boys thought that they would also be 
protected. At this high rate of protection, adding boys to the vaccination rate actually diminished 
the incremental impact the vaccine has due to the economic costs of the vaccine (Brisson et al., 
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2011). If girls were not being vaccinated at a high rate, then boys needed to be added to the 
equation to decrease the spread of HPV. 
Aggressively vaccinating boys against HPV, was as valuable to society as vaccinating 
girls, but studies like this may give pause. Though we suspected that in smaller, low-income 
communities like those we would target, would likely have poor vaccination rates, we argued 
that at some point, if efforts were successful, the vaccination of boys could be cut back or 
eliminated all-together and those funds used elsewhere. 
The researchers concluded that vaccinating boys would have an overall effect on the 
actual number of infections. Vaccinating boys would likely not be cost effective once a high rate 
of vaccination among girls was reached (Brisson et ah, 2011). 
This article showed that despite some beliefs that 100% of vaccination rates should 
always be the goal. Many factors caused the vaccination rate to diminish (age, health, belief-
systems) and therefore leave people susceptible that relying on a herd immunity model was the 
next best thing. Once the herd immunity model was adopted factors that feed into its 
effectiveness must be examined including cost, community practices, belief-systems, age and the 
health of participants. If any of the factors eliminated the effectiveness of the program, then re­
examination of the program was compulsory (Brisson et al., 2011). This article shed light on 
what some might see as hesitation to act by a government which might actually be a practical 
application of economic principles - if the return was diminished, would the investment be a 
wise one? 
Alternative Preventions and Their Efficacy. For years, condoms were touted as being 
effective in the prevention of sexually transmitted diseases. Many researchers wanted to know if 
educating target groups about the use of condoms in addition to receiving the HPV vaccine 
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would have a significant effect on the rate or HPV infections. According to Miksis (2008), the 
purpose of the meta-analysis study he carried out was to determine the efficacy of condom use 
versus the human papillomavirus (HPV) vaccine in the prevention of HPV infections. Several 
different data sources, including Cochrane, CINHAL and Clinical Evidence, were used to help 
support evidence regarding condom use versus HPV vaccination. Several studies were discussed 
throughout the article, including meta-analysis, clinical trials and random double-blinded placebo 
trials (Miksis, 2008). Random groups of English men and women were selected to participate in 
the trials. The age range included 15-25 year old men and women. "Researchers hypothesized 
that consistent protection of the cervix by a barrier method, primarily a condom, may provide 
protection even when the woman is already HPV positive" (Miksis, 2008). Condom use during 
sexual intercourse would protect the woman from additional exposure to HPV and may prevent 
the spread of genital warts in women and men. 
A cross-sectional study of HPV DNA detection in women whose husbands used condoms 
versus those who did not wear condoms, showed an 80% decrease in the likelihood of cervical 
HPV DNA detection in those who used the condoms (Miksis, 2008). Another study statistically 
showed an increased risk for HPV DNA detection among women who reported the use of 
condoms. The comparison showed that women who used condoms all or most of the time had 
50% more likelihood to have HPV DNA than those who did not use condoms. Another study 
helped support the previous one stating that women who used condoms more than 75% of the 
time versus those who used condoms 25% of the time, had an increased risk of HPV DNA 
(Manhart & Koutsky, 2002). 
Studies were reviewed to determine the relationship between condom use and the 
detection of both low-grade and high-grade cervical intraepithelial neoplasia (CIN) lesions. 
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These studies revealed mixed results. One of the studies revealed an 80% increased risk of 
squamous intraepithelial lesions among women who reported condom use. Four out of the six 
studies revealed no positive association between condom use and the development of low-grade 
CIN I. Studies revealed that women who reported any condom use with their husband were 70% 
less likely to have CIN II and CIN III compared to those women who did not use condoms. 
Another study revealed a 40% decreased risk of acquiring CIN II and III in women who used 
condoms. Women already diagnosed with CIN, who used condoms most or all of the time, were 
30% less likely to develop CIN II and 70% less likely to develop CIN III (Miksis, 2008). 
However, one of the studies showed no relationship between condom use and CIN II and 
III. Two of the studies from the meta-analysis revealed that condoms provide some protection 
against genital warts. The study included 432 male military recruits who used condoms, did not 
use condoms or used condoms sometimes during sex (Miksis, 2008). Those who reported using 
condoms most of the time were 70% less likely to have genital warts compared to those who did 
not use condoms. A study was also conducted on men and women in an STD clinic. Those who 
reported always using condoms were 60% less likely to have genital warts compared to those 
who did not use condoms. These studies revealed that women were less protected from condom 
use than men (Miksis, 2008). 
A longitudinal study conducted by Winer et al. (2006) of 82 female university students, 
ages 18-22, was conducted to evaluate the relationship between male condom use and HPV 
infections in new sexually active women. The participants reported their first intercourse with a 
male partner either during the study period or within 2 weeks prior to enrollment of the study. 
The study lasted 3 years. Women had pap smears and supplied cervical and vulvovaginal 
samples for HPV DNA at enrollment of the study and every 4 months. The women were given 
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electronic diaries to record information about their sexual experience and condom use every 2 
weeks. Studies revealed that women whose partners used condoms all the time were 70% less 
likely to acquire a new infection compared to those who used condoms less than 5% of the time. 
Women whose partners used condoms more than half of the time had a 50% decreased risk 
compared to those who used condoms less than 5% of the time. End results revealed that newly 
sexually active women whose partners use condoms have decrease risk of cervical and 
vulvovaginal HPV infection (Winer et al., 2006). 
Condoms used in the prevention of HPV infection was inconsistent compared to the HPV 
vaccine. The HPV vaccine did not protect against all types of HPV and so condom use played 
an important role in helping reduce all infections. The end results in this article revealed the 
HPV vaccine was superior to condom use in preventing HPV infection. Condoms aided in the 
prevention of HPV infection and helped protect against genital warts and other sexually 
transmitted diseases. Significant information from this article would aide in providing education 
to males who are in age range for the HPV vaccine. The information in this article provided a 
good argument in condom use versus HPV vaccination. Based on results from this article, 
researchers concluded that the HPV vaccine benefited more than condom use in prevention of 
HPV infection. Condoms helped reduce transmission of sexually transmitted diseases. Strengths 
of the article concluded that condoms and the HPV vaccine would be ideal in HPV infection 
prevention. This information could be used in our group's research project and in clinics. 
Males, parents and health care providers benefited from the information revealed in the article. 
Barriers to the article included the small sample size and not having "true and reliable" 
information from the participants who were studied (Winer et al., 2006). In argument of 
condoms versus HPV vaccine, the combo of the two won. 
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Summary 
The HPV vaccine is still in its infancy with the evidence of its effectiveness lying far in 
the future. Current studies revealed that there is still much to learn about several issues 
surrounding the vaccine: low awareness, barriers to obtaining the vaccine and the long term 
immunity and effectiveness just to name a few. As researchers struggled to glean information 
from both the public and the scientific community regarding the long term effects of the vaccine, 
one thing was certain - much higher percentages of the target populations must be reached in 
order to maximize effectiveness. Programs insuring education and availability provided the 
critical link between the past where HPV and its lifelong side effects existed and the future 
where the HPV vaccine had hopefully eradicated the infection and all of its requisite cancers. 
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Chapter III 
Design and Methodology 
Introduction 
The purpose of this study was to determine if boys, ages 9-21, were educated about the 
HPV vaccine at their local community clinic and if the vaccine was administered. This study 
assessed a small element of a problem which was causing an increase in the number of people 
diagnosed with an often fatal cancer primarily caused by a preventable sexually transmitted 
disease, human papillomavirus. According to the Department of Health and Human Services 
(2012), an estimated 5.5 million new cases of HPV are reported in the U.S. each year and at least 
20 million Americans are infected. HPV is transmitted sexually across genders, meaning that an 
increase in male HPV infections increased chances of females contracting HPV infections. On 
October 16. 2009, The U.S. Food and Drug Administration (FDA) approved use of the vaccine 
Gardasil® (Human Papillomavirus Quadrivalent) for the prevention of genital warts (condyloma 
acuminata) due to human papillomavirus types 6 and 11 in boys and men. ages 9-26 (FDA, 
2009). Human papillomavirus quadrivalent's effectiveness was studied in a randomized trial of 
4,055 boys, ages 16-26 years old. The results showed that in men who were not infected by 
HPV types 6 and 11 at the start of the study, human papillomavirus quadrivalent was nearly 90 
percent effective in preventing genital warts caused by infection with HPV types 6 and 11 (FDA, 
2009). According to Melville (2012), very few parents had their adolescent sons vaccinated for 
HPV in the year after its approval. Moreover, the willingness of parents to have their sons 
vaccinated appeared to decline over time (Melville, 2012). The strongest predictor of being 
vaccinated was the recommendation from a physician. Of those who recommended the vaccine, 
55% were vaccinated and only 10% reported receiving a recommendation (Melville, 2012). 
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Design and Setting 
The study was a quantitative, retrospective chart review to determine adherence to the 
CDC recommendations of administering the Gardasil® vaccine to boys, ages 9-21. Researchers 
had each ot their participating clinics sign a letter of consent stating acceptance of participation 
(Appendix A). Data were obtained from 300 charts of boys, ages 9-21, in three primary care 
health clinics. At the first clinic, the staff included 1-nurse practitioner and 2-physicians. 
Approximately 60 patients were seen at Clinic One per day. The head nurse over the vaccination 
program printed off an electronic list of males between the ages of 9-21. From the list, the head 
nurse picked every fifth chart until a total of one hundred charts were reached. The second clinic 
had 1-physician. Approximately 20 patients were seen at Clinic Two per day. The receptionist 
printed off an electronic list of male patients, age 9-21. The receptionist allowed the researcher 
to pick every fifth chart until a total of one hundred charts were reached. The third clinic had 1-
nurse practitioner and 1-physician. Approximately 30 patients were seen at Clinic Three per day. 
The receptionist printed off an electronic list of males, age 9-21. The researcher picked every 
fifth chart until a total of one hundred charts were reached. Charts were respectively reviewed 
and maintained within the clinic. The charts were reviewed to determine the number of boys, 
ages 9-21, who were educated on the HPV vaccine and who received the HPV vaccine. 
Population and Sample 
The selected sample was taken from three rural primary care health clinics located in the 
southeastern United States. Boys, who were 9-21 years of age, met the criteria to be included in 
the research project. The sample for this research study was chosen based on the CDC's 
recommendations of vaccination beginning as early as age 9 for boys (Appendix B). 
Recommendations were also for boys, ages 13-21, who had not already received the HPV 
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vaccine (CDC, 2012). A convenience sample was utilized in each of the three clinics until 300 
medical records were obtained. Researchers used the data collection worksheet to document data 
collected (Appendix C). The collected data was stored on a spread sheet and saved to a 
password protected computer and zip-drive. 
Protection of Human Subjects 
In an effort to maintain confidentiality and maintain individual rights, all identifying 
information was excluded on the data collection worksheet. The information obtained was kept 
confidential through a password locked computer which was accessible only by the researchers. 
The information was then saved to a password protected zip drive which was kept safe by the 
researcher. The data collection worksheet was shredded after information was entered into the 
computer. Approval for this research project was obtained from the Mississippi University for 
Women's Institutional Review Board. 
Statistical Analysis 
During the chart review, the researchers used the Data Collection Worksheet (Appendix 
C) to gather information regarding the research problem. After the researchers collected the data 
using the worksheet, the data was analyzed. Using percentages, the researchers determined the 
number of boys who received the HPV vaccine, did not receive the HPV vaccine, received 
education on the HPV vaccine or did not receive education. The researchers also determined 
which type of education was provided to the patient. Analysis of the researchers' proposed 
questions was completed. 
Summary 
The researchers reviewed a total of 300 charts at three clinics in the southeastern United 
States for assessment of determining the number of males, ages, 9-21, who were educated on the 
HPV vaccine and who received the vaccine. All study participants remained anonymous. The 
information was documented on the data collection worksheet. The researchers examined each 
selected medical record to determine if the boys were educated on or received the HPV vaccine. 
The researchers determined which type of education was provided to the patient. The 
information collected was used to determine if males, ages 9-21, were vaccinated with HPV or 
taught about the importance of vaccination. 
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Chapter IV 
Presentation of Findings 
The purpose of this study was to determine if boys, ages 9-21, were educated about the 
HPV vaccine at their local community clinic and if the vaccine was administered. The 
researchers evaluated if males, age 9-21, received the HPV vaccine or received education about 
the importance of the HPV vaccine. If education was provided to the patient, researchers 
evaluated which type of education was provided. This chapter provides a description of the 
researchers' samples, demographics and analysis of the data collected. The findings are 
presented in the form of pie charts and percentages. 
Description of the Sample 
The data for this study was gathered by reviewing a total of 300 randomly selected charts 
on males, ages 9-21 from three different clinics in the southeastern United States. Researchers 
determined if the HPV vaccine was given to the patient, if education was provided and what type 
of education was provided. The data collection sheet (Appendix C) was used to record the 
information and included the clinic, provider, age and ethnicity of the patient and the payer 
source. Researchers concluded final results with a percentage of each section from the data 
worksheet. 
Data Analysis and Results 
The average age for patients who received the HPV vaccine during this study was age 13. 
All three of the clinics had physicians who served as a provider prescribing and offering the HPV 
vaccine. The majority of the patients who received the HPV vaccine were African American 
(65%) and the rest were Caucasian (30%) or other ethnicities (5%). The payer sources identified 
included Medicaid (85%), Private Insurance (10%) and Self pay (5%). Pie charts represent the 
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other data that was collected. Each figure showed a percentage amount from the 300 charts 
reviewed. 
Below displays the total results of the male patients who received or did not receive the 
HPV vaccine. Of the 300 charts reviewed, 25% received the HPV vaccine and 75% did not 
receive the HPV vaccine. (See Figure 1) 
HPV Vaccine Given 
• YES •  NO 
Figure 1 HPV Vaccine Given 
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The pie chart below demonstrates the type of education that was provided to the patients 
about the HPV vaccine. From the 300 charts reviewed and out of the 40% who received 
education, 75% received a verbal recommendation from the provider, 20% received a pamphlet 
and 5% received a printout about HPV. (See Figure 3) 
Type of Education 
m  V e r b a l  
P a m p h l e t  
•  P r i n t  O u t  
Figure 3. Type of Education 
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Summary of Findings 
After all results were determined from the 300 charts reviewed, only 25% of male 
patients, ages 9-21, received the HPV vaccine. Only 40% of male patients received education 
about the recommendations for the HPV vaccine and 75% of the education was verbal 
recommendations. The average age of male patients who received the HPV vaccine was age 13. 
Majority of those vaccinated were African American, had Medicaid as the payer source and were 
seen by a physician. 
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Chapter V 
Summary and Conclusions 
Human papillomavirus (HPV) affects many people in the United States. HPV is known 
as one ot the most commonly spread STI's among young adults. Men do not show any 
symptoms of the HPV virus and are not aware that they carry the virus. The HPV vaccine has 
been available for the past several years to prevent spread of the virus not only for females but 
also for males (CDC, 2012). 
The purpose of this study was to determine if boys, ages 9-21, were educated about the 
HPV vaccine at their local community clinic and if the vaccine was administered. The data for 
this study came from the 300 chart reviews performed at the three primary health care clinics in 
the southeastern United States. Physicians and nurse practitioners were the providers at these 
clinics. The information collected and reviewed was shared with the providers to help benefit 
their practice. This study helped to recognize areas for improvement on providing patients 
necessary information on receiving the HPV vaccine based on the Centers for Disease Control 
and Prevention's recommendations. Administering the HPV vaccine will help lower the rates of 
HPV, cervical cancer and genital warts. 
The sample population consisted of 300 medical records of males, ages 9-21. The charts 
were reviewed by the researchers. The researchers recorded information on the Data Collection 
worksheet (Appendix C). Components of this form included: age, ethnicity, payer source, 
physician or nurse practitioner, if HPV vaccine was given or prescribed, if education was 
provided about HPV and what type of education was provided. Descriptive statistics were used 
to present the concluded data as to whether or not providers followed the CDC's 
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recommendations for providing males, ages 9-21 with the HPV vaccine or providing education 
on the importance of the vaccine. 
Interpretation of Findings and Conclusions 
The review of literature performed by each researcher showed evidence that HPV was 
known as a widely spread STI which caused different types of cancers. The reviews showed that 
parents were unaware that their sons could be vaccinated with the HPV vaccine and were 
interested in learning more about recommendations. Evidence from our research revealed that 
parents were not aware of the CDC's recommendations for HPV vaccination in males. Results 
from our research were compared to studies by Cates et al. (2012) showed an important demand 
for education of health care providers. Based on findings by Cates et al. (2012), the HPV 
vaccination should be taught at all wellness visits to males and females starting at age 9. Results 
from our research study showed that only 25% of males in the age range of 9-21 received the 
HPV vaccine. Evidence from studies by Cates et al. (2012) showed that males who received the 
HPV vaccination helped to lower the spread of HPV related infections. Only 40% of the patients 
from our study received education from the provider about the importance and recommendation 
for the HPV vaccine. The majority of the education given to the patients was verbal (75%) 
education. The literature by Cates et al. (2012) showed evidence that parents preferred seeing 
actual written information about why they should vaccinate their sons along with a good 
explanation from the health care provider. Our research group thought that more male patients 
would be vaccinated. We were not surprised by the type of education provided to patients. 
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Implications for Nurse Practitioners 
The CDC (2012) recommends the HPV vaccine be given to males, age 9-21. The 
researchers concluded that of the 300 charts reviewed only 25% of males, age 9-21, received the 
HPV vaccine. The average age at vaccination was 13 years old. Only 40% received education 
on the CDC's recommendations for the HPV vaccine which concluded that 75% were verbally 
informed. These patients received no education material to take home and read. The patient or 
parent would need to research the need for the HPV vaccine through resources that may not be 
helpful or true. All healthcare providers need to provide male and female patients starting at age 
9 and to their parents information on the CDC's recommendations for receiving the HPV vaccine 
along with other required vaccines. The provider had the responsibility to ensure patients 
received the vaccine in a series of 3 shots at appropriate times. 
This study was conducted by researchers to determine if boys, ages 9-21, were educated 
about the HPV vaccine at their local community clinic and if the vaccine was administered, 
provide evidence to providers for the need and CDC's recommendations for vaccinating males 
with the HPV vaccine. Results from the study were shared with the clinics to help improve 
compliance with CDC guidelines and recommendations. Researchers discussed with providers 
the importance of educating their patients and parents about the HPV vaccine and the need to 
hand out written material for the patient to take home and read. The provider was taught the 
importance to ensure that the parent understands all the information provided to them. Providers 
were appreciative of the information provided to them from the researchers. The providers 
discussed the need to promote the HPV vaccination for males in their clinic. 
Recommendations 
1. Repeat the study using a larger sample size at each clinic would be beneficial with better 
results 
2. Recommend the HPV vaccine in the series of vaccines at routine visits to help improve 
compliance 
3. More financial aid from insurance companies would benefit compliance with the HPV 
vaccination 
4. Broadening the sample to males and females would provide more comparable statistics 
5. Providing every patient with written pamphlets or print outs about the CDC's 
recommendations for HPV vaccination along with actual statistics would benefit patients 
and parents 
6. Adding a qualitative review about parents and patients opinions on receiving or not 
receiving the HPV vaccine would add more details to the final results. The qualitative 
review could help to determine whether or not providing education from providers was 
beneficial or not to the patient. 
Summary of Discussion and Implications 
In conclusion, the current research project determined if boys, ages 9-21, were educated 
about the HPV vaccine at their local community clinic and if the vaccine was administered. 
Medical records of 300 patients were reviewed to determine if the HPV vaccine was given, if 
education was provided about the vaccine and what type of education was provided. After data 
was resulted, the researchers determined that the majority of males, age 9-21, did not receive the 
HPV vaccine. Furthermore, education was not provided to every patient reviewed. Verbal 
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information was beneficial but may not be considered anymore after the visit. Providing written 
information by pamphlet or a printout with the CDC's recommendations and current statistics 
would have improved compliance with the HPV vaccination. Educating parents and patients at 
routine visits could help to aid in compliance with healthcare recommendations. 
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APPENDIX A 
Letter of Consent 
Date: 
A family practice clinic in a southern state 
SUBJECT: Permission to participate in a research project 
We are graduate students in the family nurse practitioner program at Mississippi 
University for Women in Columbus, MS. As a program requirement, we are conducting a 
retrospective chart review to assess whether or not boys, ages 9-21, are being vaccinated with the 
HPV vaccine. We are also assessing if they are being educated on the importance of the HPV 
vaccine. The students which are participating in this research project are Lacey Gullick, Kevin 
Miller and Laura Phillips. 
Your participation will involve granting us the privilege of reviewing medical records of 
your clients between the ages of nine and twenty one. As researchers, we understand that we 
must maintain the confidentiality of all information collected from the charts. This information 
includes, but is not limited to, all identifying information and research data that we will come 
into contact with while performing chart reviews. We agree to refrain from discussing or 
disclosing any information regarding your clients. Each researcher will receive Human Insurance 
Portability and Accountability (HIPAA) training, and Corporate Compliance training through the 
facility before beginning the research. The study includes a retrospective chart review following 
HIPPA guidelines and will not involve human participants. The chart reviews will be recorded 
on a Data Collection Worksheet. The information will be entered into a computer data sheet. The 
data sheet will be saved to a portable jump drive which will be kept in a locked area. This area 
will only be accessible by the researchers. After completion of the project, all physical data will 
be destroyed appropriately. The results of this study may be published, but your name, the clinic, 
nor any of the patient's information will be identifiable. 
Your participation in this study is strictly voluntary. The possible benefit of your 
participation is that the research project will serve as a quality assurance measure for you. The 
amount of time required for us to review charts and collect data will be approximately one 
month. After the research project is complete, we will provide you with the results from the 
study. 
If you have any questions concerning this research study, please call Lacey Gullick at 
(662) 934-6903, Kevin Miller at (662) 610-5633, Laura Phillips at (870) 995-8664 or contact the 
chair of our research committee, Dr. Carey McCarter, at (662) 329-7466. In addition, you may 
withdraw your consent and participation in this study at any time by contacting one of us or the 
chair of our research committee. 
Sincerely, 
Lacey Gullick, Kevin Miller and Laura Phillips 
I have read this letter of consent and have been given the opportunity to ask questions. I give my 
consent to participate in the above study. 
Clinic Manager Signature Date 
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APPENDIX B 
CDC Guidelines for HPV Vaccine 
VACCINE INFORMATION STATEMENT 
HPV (Human Papillomavirus) Vaccine Gardasil 
What You Need to Know: 
Many Vaccine Information Statements are available in Spanish and other languages. See 
www.immunize.org/vis. 
1. What is HPV? 
Genital human papillomavirus (HPV) is the most common sexually transmitted virus in the 
United States. More than half of sexually active men and women are infected with HPV at 
some time in their lives. 
About 20 million Americans are currently infected, and about 6 million more get infected each 
year. HPV is usually spread through sexual contact. 
Most HPV infections don't cause any symptoms, and go away on their own. But HPV can 
cause cervical cancer in women. Cervical cancer is the 2nd leading cause of cancer deaths 
among women around the world. In the United States, about 12,000 women get cervical cancer 
every year and about 4,000 are expected to die from it. 
HPV is also associated with several less common cancers, such as vaginal and vulvar cancers in 
women, and anal and oropharyngeal (back of the throat, including base of tongue and tonsils) 
cancers in both men and women. HPV can also cause genital warts and warts in the throat. 
There is no cure for HPV infection, but some of the problems it causes can be treated. 
2. HPV vaccine: Why get vaccinated? 
The HPV vaccine you are getting is one of two vaccines that can be given to prevent HPV. It 
may be given to both males and females. 
This vaccine can prevent most cases of cervical cancer in females, if it is given before exposure 
to the virus. In addition, it can prevent vaginal and vulvar cancer in females, and genital warts 
and anal cancer in both males and females. 
Protection from HPV vaccine is expected to be long-lasting. But vaccination is not a substitute 
for cervical cancer screening. Women should still get regular Pap tests. 
3. Who should get this HPV vaccine and when.' 
Routine Vaccination: 
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• This HPV vaccine is recommended for girls and boys 11 or 12 years of age. It may be given 
starting at age 9. 
Why is HPV vaccine recommended at 11 or 12 years of age? 
HPV infection is easily acquired, even with only one sex partner. That is why it is important to 
get HPV vaccine before any sexual contact takes place. Also, response to the vaccine is better at 
this age than at older ages. 
Catch-Up Vaccination: 
This vaccine is recommended for the following people who have not completed the 3-dose 
series: 
Females 13 through 26 years of age. 
Males 13 through 21 years of age. 
This vaccine may be given to men 22 through 26 years of age who have not completed the 3-
dose series. 
It is recommended for men through age 26 who have sex with men or whose immune system is 
weakened because of HIV infection, other illness, or medications. 
HPV vaccine may be given at the same time as other vaccines. 
HPV vaccine is given in a 3-dose series: 
1st Dose Now dose 
2nd Dose 1 to 2 months after Dose 1 
3rd Dose 6 months after Dose 1 
APPENDIX C 
Data Collection Worksheet 
1. Clinic: 
0) Clinic 1 
1) Clinic 2 
2) Clinic 3 
2. Age: 9 10 11 12 13 14 15 16 17 18 19 20 21 













3) Private Insurance 
4) Self pay 
6. Was education provided about the HPV vaccine? 
0) No 
1) Yes 
7. What type of education was provided? 
0) Verbal 
1) Pamphlet 
2) Immunization printout 
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